Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$4.49
-2.0%
$5.00
$3.42
$7.20
$257.46M1.751.55 million shs692,364 shs
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$4.12
-0.2%
$3.36
$2.01
$5.64
$274.75M1.521.21 million shs838,205 shs
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$1.63
-3.6%
$1.79
$1.32
$2.72
$246.81M1.71160,008 shs58,277 shs
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
$2.27
-2.2%
$1.77
$0.87
$9.25
$77.88M0.25847,844 shs848,634 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-1.97%-1.54%-23.25%+3.46%-26.27%
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-0.24%+4.57%+8.14%+46.62%+64.14%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
-3.55%-4.12%-6.32%+12.41%-20.10%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-2.16%+20.11%+24.73%+65.69%-73.14%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.2932 of 5 stars
0.01.00.00.02.60.80.6
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
1.2399 of 5 stars
3.40.00.00.02.00.00.6
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
1.5028 of 5 stars
3.51.00.00.03.30.00.0
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
2.2906 of 5 stars
3.44.00.00.02.10.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
3.67
Strong BuyN/AN/A
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
2.83
Moderate Buy$11.70183.98% Upside
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
3.00
Buy$7.00329.45% Upside
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
2.80
Moderate Buy$9.60322.91% Upside

Current Analyst Ratings Breakdown

Latest OTLK, ACB, IMMP, and CRDF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$19.00
6/24/2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold$3.50
6/18/2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
6/6/2025
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$24.00 ➝ $21.00
5/20/2025
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/9/2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$17.00 ➝ $18.00
(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$343.29M0.74$0.60 per share7.49$7.78 per share0.58
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$680K403.09N/AN/A$1.86 per share2.22
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/AN/AN/AN/A$1.05 per shareN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
N/AN/AN/AN/A($3.09) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$1.63M$0.1140.8210.20N/A1.32%0.13%0.10%8/6/2025 (Estimated)
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$45.43M-$0.92N/AN/AN/A-8,308.50%-76.45%-62.85%8/14/2025 (Estimated)
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
-$28.01MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-$75.37M-$0.91N/AN/AN/AN/AN/A-271.12%8/13/2025 (Estimated)

Latest OTLK, ACB, IMMP, and CRDF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q3 2025
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-$0.42N/AN/AN/A$1.66 millionN/A
8/6/2025Q1 2026
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$0.18N/AN/AN/A$96.83 millionN/A
6/18/2025Q4 2025
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$0.11$0.07-$0.04-$0.24$88.85 million$63.34 million
5/15/2025Q2 2025
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-$0.55-$0.40+$0.15-$1.50$0.70 millionN/A
5/8/2025Q1 2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$0.19-$0.20-$0.01-$0.20$0.09 million$0.11 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
N/AN/AN/AN/AN/A
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
N/AN/AN/AN/AN/A
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/AN/AN/AN/AN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.13
4.31
2.16
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
N/A
6.22
6.22
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/A
18.86
N/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
N/A
0.72
0.57

Institutional Ownership

CompanyInstitutional Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
47.63%
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
16.29%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2.32%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
11.20%

Insider Ownership

CompanyInsider Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.01%
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
7.70%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
3.07%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
4.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
1,13056.21 million56.21 millionOptionable
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
2066.53 million61.40 millionOptionable
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2,021146.04 million141.56 millionOptionable
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
2033.57 million31.96 millionOptionable

Recent News About These Companies

Brokerages Set Oncobiologics, Inc. (NASDAQ:OTLK) Target Price at $9.60
OTLK Outlook Therapeutics, Inc. - Seeking Alpha
Outlook’s wet AMD treatment accepted by SMC for NHS Scotland
Highlights | Outlook Planet’s C³ Summit & Awards 2025

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurora Cannabis stock logo

Aurora Cannabis NASDAQ:ACB

$4.49 -0.09 (-1.97%)
Closing price 07/15/2025 04:00 PM Eastern
Extended Trading
$4.50 +0.01 (+0.22%)
As of 08:24 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Cardiff Oncology stock logo

Cardiff Oncology NASDAQ:CRDF

$4.12 -0.01 (-0.24%)
Closing price 07/15/2025 04:00 PM Eastern
Extended Trading
$4.20 +0.08 (+1.82%)
As of 08:22 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Prima BioMed stock logo

Prima BioMed NASDAQ:IMMP

$1.63 -0.06 (-3.55%)
Closing price 07/15/2025 04:00 PM Eastern
Extended Trading
$1.64 +0.01 (+0.61%)
As of 07/15/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Oncobiologics stock logo

Oncobiologics NASDAQ:OTLK

$2.27 -0.05 (-2.16%)
Closing price 07/15/2025 04:00 PM Eastern
Extended Trading
$2.28 +0.01 (+0.44%)
As of 08:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.